Browse Articles

Single-cell data from RNA-seq, chromatin accessibility, DNA methylation and other modalities can be readily integrated using two new methods.

Mosaic data integration is improved by capturing features that do not overlap between datasets.

Reference mapping is extended beyond scRNA-seq to single-cell epigenetic and proteomic data.

A sequencing chemistry that separates nucleotide identification from nucleotide incorporation achieves high accuracy.

A cancer vaccine is delivered to the lung by an engineered attenuated influenza virus.

Bacteria and viruses are simultaneously quantified in gut metagenomic samples.

The fusion of a programmable transcription-activator-like effector (TALE) protein with a nickase, in conjunction with a deaminase, enables efficient and strand-selective DNA base editing. This approach has the potential to advance our understanding and treatment of diseases associated with mutations in the mitochondrial or nuclear genome.

Minigraph-Cactus, a method to efficiently combine multiple reference genome assemblies into a pangenome reference graph, can be used to improve accuracy of read mapping and variant calling compared with a single reference in downstream applications.

GlycoRNA imaging in cells is enabled with a proximity ligation assay.

A wearable ultrasound patch monitors subjects in motion using machine learning and wireless electronics.

Mitochondrial point mutations are corrected in human cells using a transcription activator-like effector (TALE)-based system.

SEACells identifies rare cell states in large datasets, enabling atlas-scale studies.

By linking transgene expression with that of a housekeeping gene, SLEEK (selection by essential-gene exon knock-in) enables efficient knock-in of complex cargos in a variety of clinically relevant cell types. Using SLEEK, we were able to substantially improve the tumor suppression ability and in vivo persistence of a cell therapy.

Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success. Companies differ on how to move the resurgent field forward.